Incyte eyes first-line nod for Tafasitamab in aggressive lymphoma
Diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma (NHL) in adults, represents 40% of all cases worldwide
Diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma (NHL) in adults, represents 40% of all cases worldwide
Heart failure affects an estimated 64.3 million people worldwide
GlideTech materials are available in several standard base resins and offer customization options for specific applications
Rajdeep is an accomplished business leader with a strong techno-commercial background in the healthcare and diagnostic sector
India’s pharmaceutical sector stands at a pivotal inflection point
Pravesh brings with him over 29 years of experience in leading complex manufacturing operations and driving operational excellence
Within India, Dabur expects its Home & Personal Care business to deliver double-digit growth,
The company is pursuing the accelerated FDA 505(b)(2) approval pathway for its once-daily oral ondansetron formulation
Under the agreement, Insilico could receive up to $32 million in upfront and near-term R&D payments
Valneva said regaining full rights to the vaccine will allow the company to “assume direct control over its supply chain and commercialization for endemic high-risk countries
Subscribe To Our Newsletter & Stay Updated